LINC01355: A Drug Target / Disease Biomarker (G100996511)

Target Name: LINC01355

NCBI ID: G100996511

LINC01355

Other Name(s): HYPAL | Long intergenic non-protein coding RNA 1355 | long intergenic non-protein coding RNA 1355

LINC01355: A Drug Target / Disease Biomarker

LINC01355 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a key regulator of cell growth and differentiation, and has been identified as a potential drug target for various diseases.

One of the most promising aspects of LINC01355 is its ability to interact with a variety of signaling pathways. LINC01355 has been shown to play a role in several signaling pathways that are important for cell growth, including the TGF-β pathway and the Wnt pathway.

The TGF-β pathway is a well-established signaling pathway that is involved in cell growth, differentiation, and repair. This pathway is important for the development and maintenance of tissues, and is often disrupted in diseases such as cancer. LINC01355 has been shown to play a role in regulating TGF-β signaling by inhibiting the activity of the transcription factor SMAD.

The Wnt pathway is a signaling pathway that is involved in cell growth and development. LINC01355 has been shown to be involved in this pathway, and has been shown to play a role in the development and maintenance of tissues.

Another promising aspect of LINC01355 is its ability to interact with the protein PDGFR. PDGFR is a protein that is involved in cell growth and development, and is often disrupted in diseases such as cancer. LINC01355 has been shown to play a role in regulating PDGFR signaling by inhibiting the activity of the protein SHC-1.

In addition to its role in signaling pathways, LINC01355 has also been shown to have a variety of functional roles in cells. For example, LINC01355 has been shown to play a role in regulating the formation of new blood vessels in the liver, which is important for the treatment of diseases such as alcoholism and nonalcoholic steatohepatitis.

LINC01355 is also of interest as a potential biomarker for several diseases. For example, LINC01355 has been shown to be expressed in the liver, and has been associated with the development of liver cancer. Additionally, LINC01355 has been shown to be expressed in the kidneys, and has been associated with the development of kidney disease.

In conclusion, LINC01355 is a protein that has been identified as a potential drug target for several diseases. Its ability to interact with signaling pathways and to have functional roles in cells makes it an attractive target for research into the development of new treatments. Further research is needed to fully understand the role of LINC01355 in disease, and to determine its potential as a drug.

Protein Name: Long Intergenic Non-protein Coding RNA 1355

The "LINC01355 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01355 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets